The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia | Aplastic Anemia & MDS International Foundation Return to top.

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

Journal Title: 
Seminars in Hematology
Primary Author: 
Gonzalez-Lugo J
Author(s): 
Jesus D Gonzalez-Lugo, Samarpana Chakraborty, Amit Verma, Aditi Shastri
Original Publication Date: 
Friday, January 1, 2021

Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeutics that have changed the treatment landscape of MDS and AML, significantly improving outcomes. In this review we describe the most common epigenetic aberrations in MDS and AML, and current treatments that target mutations in epigenetic modifiers, as well as novel treatment combinations, from standard therapies to investigational treatments.

Share with addtoany.com.